First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

ALT-101 is a first-in-human Phase 1 clinical trial testing a new antibody drug called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. 4A10 is a targeted therapy designed to recognize and attach to a specific protein (CD127) found on leukemia cells. Once it binds, it works in two ways: it blocks growth signals that help cancer cells survive, and it helps the immune system find and destroy those cancer cells. In this study, patients receive 4A10 through an intravenous (IV) infusion once a week. The main goal of the trial is to find

Trial Details

NCT ID

NCT07586618

Phase

PHASE1

Sponsor

Allterum Therapeutics, Inc

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• 4A10

Locations (sample)

• Aurora, Colorado, United States|39.72943,-104.83192
• New York, New York, United States|40.71427,-74.00597
• Philadelphia, Pennsylvania, United States|39.95238,-75.16362
• Fort Worth, Texas, United States|32.72541,-97.32085
• Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

• Confirmed diagnosis of T/B-ALL or T/B-LL
• Relapsed or refractory disease without curative options
• Adequate organ function and performance status
• Key Exclusion Criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →